Largactil Im

Chlorpromazine, the active ingredient in Largactil Im, is a phenothiazine presented as an intramuscular preparation for injection use. It is employed to manage schizophrenia, acute psychotic episodes, severe agitation, and nausea or vomiting, providing antipsychotic and antiemetic effects in adult patients and is available in multiple dosage strengths for clinical flexibility.

GNH USA supplies Largactil Im as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Chlorpromazine is used in the treatment of several psychiatric and gastrointestinal conditions by modulating dopaminergic pathways.

Schizophrenia: reduces psychotic symptoms and stabilizes mood. Acute psychotic episodes: rapidly controls agitation and hallucinations. Severe agitation: calms extreme restlessness and aggressive behavior. Nausea and vomiting: acts as an antiemetic to relieve chemotherapy‑induced or postoperative nausea.

Chlorpromazine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Sedation or drowsiness - Orthostatic hypotension - Dry mouth and constipation - Extrapyramidal symptoms such as tremor or rigidity - Blurred vision

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe cardiac arrhythmias or QT prolongation - Agranulocytosis - Tardive dyskinesia - Seizures

When prescribing chlorpromazine, clinicians should observe several safety measures to minimize risks.

Monitor blood pressure: watch for orthostatic hypotension, especially after first doses. Assess for extrapyramidal symptoms: regular neurological examinations. Evaluate cardiac status: ECG monitoring for QT prolongation. Use caution in elderly: increased susceptibility to sedation and falls. Avoid abrupt discontinuation: taper dose to prevent withdrawal. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Chlorpromazine interacts with several drug classes, requiring careful management to avoid harmful effects.

Major Interactions (Avoid): - CNS depressants (e.g., barbiturates, opioids) – additive sedation. - Antiarrhythmics (e.g., quinidine) – increased risk of arrhythmia. - QT‑prolonging agents (e.g., haloperidol) – heightened cardiac risk. - MAO inhibitors – severe hypotension. - Anticholinergic agents – excessive anticholinergic burden.

Moderate Interactions (Monitor Closely): - Antihypertensives – enhanced hypotensive effect. - Antidiabetic agents – may mask hypoglycemia. - Alcohol – increased sedation. - CYP1A2 inhibitors (e.g., fluvoxamine) – raise chlorpromazine levels. - CYP2D6 substrates (e.g., metoprolol) – altered metabolism.